glycopyrronium tosylate glycopyrronium tosylate glycopyrronium tosylate, sold under the brand name qbrexza among others, is a medication used for the treatment of primary axillary hyperhidrosis. glycopyrronium tosylateclinical datatrade namesqbrexza, rapifortother namesglycopyrronium tosilate hydrate (jan jp)ahfs/drugs.commonographlicense data us dailymed: glycopyrronium routes ofadministrationtopicaldrug classmuscarinic antagonistatc coded11aa01 (who) legal statuslegal status us: ℞-only in general: ℞ (prescription only) identifierscas number1624259-25-1pubchem cid121225724drugbankdbsalt002800chemspider58902513unii1pvf6jlu7bkeggd10939chemblchembl3707243chemical and physical data3d model (jsmol)interactive image smiles o.cc1ccc(cc1)s(=o)(=o).c2(c)cc(c2)oc(=o)(o)(c3cccc3)c4ccccc4 inchi inchi=1s/c19h28no3.c7h8o3s.h2o/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;1-6-2-4-7(5-3-6)11(8,9)10;/h3-5,8-9,16-17,22h,6-7,10-14h2,1-2h3;2-5h,1h3,(h,8,9,10);1h2/q+1;;/p-1/t17-,19-;;/m0../s1key:uowolensdismpg-ffuvtkdnsa-m it was approved for medical use in the united states in june 2018, and in japan in january 2022.